Recruiting Rheumatoid Arthritis Studies in Boulder
About Rheumatoid Arthritis Clinical Trials in Boulder
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.
There are currently 1 rheumatoid arthritis clinical trials recruiting participants in Boulder, CO. These studies are seeking a combined 100,000 participants. Research is being sponsored by TransMedics. Clinical trial participation is free and participants receive study-related medical care at no cost.
Rheumatoid Arthritis Clinical Trials in Boulder — FAQ
Are there rheumatoid arthritis clinical trials in Boulder?
Yes, there are 1 rheumatoid arthritis clinical trials currently recruiting in Boulder, CO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Boulder?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boulder research site will contact you about next steps.
Are clinical trials in Boulder free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boulder studies also compensate for your time and travel.
What rheumatoid arthritis treatments are being tested?
The 1 active trials in Boulder are testing new therapies including novel drugs, biologics, and treatment approaches for rheumatoid arthritis.
Data updated July 13, 2026 from ClinicalTrials.gov